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1430Background: CollagenaseClostridium histolyticum (CCH) is indicated for the treatment of penile curvature in adult
men with Peyronie’s disease (PD) with palpable plaque and curvature deformity of at least 30 at the start of therapy.
Aim: To evaluate the efﬁcacy and safety of CCH plus vacuum-pump therapy with and without penile modeling
for the management of PD.
Methods: Adult men with PD and penile curvature of at least 30 were randomly assigned to receive CCH 0.58 mg
plus vacuum therapy alone (n ¼ 15) or with penile plaque modeling (n ¼ 15). Patients received no more than four
treatment cycles (cycle ¼w6-week duration), each consisting of two intralesional injections of CCH administered 24
to 72 hours apart. Vacuum therapy was applied twice daily from 14 days after the second injection of each cycle until
the following cycle. Modeling was performed 24 to 72 hours after the second injection of each cycle.
Outcomes: The primary end point was change in penile curvature from baseline to week 36; additional end
points included changes in Peyronie’s Disease Questionnaire (PDQ) domain scores, composite response (20%
decrease in penile curvature and decrease in PDQ bother score  1 point), and global response (small but
important, moderate, or much improvement in the Global Assessment of PD).
Results: At week 36, improvement in penile curvature from baseline was similar in the two groups (mean change
from baseline ¼ 23.7 [SD ¼ 10.9] for CCH þ vacuum þ modeling and 23.3 [SD ¼ 7.2] for CCH þ
vacuum; between-group difference ¼ 0.3, 95% CI ¼ 7.3 to 6.6). Improvements in most PDQ domains,
including bother, were observed from baseline to week 36 in the two groups. Most patients were composite (66.7%
and 84.6% with CCH þ vacuum þ modeling and CCH þ vacuum, respectively) and global (86.7% and 92.3%,
respectively) responders. The most common adverse events were penile contusion, penile swelling, and penile pain.
Clinical Implications: Vacuum-pump therapy administered alone or in combination with modeling after CCH
treatment could improve PD symptoms.
Strengths and Limitations: This was a pilot study with a small sample and limited follow-up duration.
Conclusion: CCH and vacuum-pump therapy (alone or combined with modeling) could be an appropriate
consideration for men with PD and warrants further investigation. Ralph DJ, Abdel Raheem A, Liu G.
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Peyronie’s disease (PD) is a ﬁbrotic disorder of the penis that is
believed to develop as a response to abnormal wound healing after
trauma or microtrauma.1 PD is characterized by ﬁbrosis of the
tunica albuginea, which results in the formation of plaque and the
development of penile deformity (particularly curvature) thatJ Sex Med 2017;14:1430e1437
CCH and Vacuum Therapy in Peyronie’s Disease 1431might or might not be accompanied by pain.1,2 Although once
considered a rare condition, the current prevalence of PD could be
as high as approximately 20%, depending on how the condition is
deﬁned and the population is studied.2 The symptoms of PD, and
the potential effect of the condition on erectile function, can cause
marked psychosocial stress.3 Importantly, in most cases, this stress
persists throughout the course of the disease, indicating that men
with PD do not naturally adapt to the psychological distress
associated with the condition.3 The management of stable PD
consists of different pharmacologic and surgical approaches,
depending on the severity of the penile deformity and associated
symptoms.1 Surgery is often reserved for the most serious cases4;
however, evidence to support the efﬁcacy of most current non-
invasive or minimally invasive therapies is limited.1,4
Collagenase Clostridium histolyticum (CCH; Xiaﬂex, Endo
Pharmaceuticals, Inc, Malvern, PA, USA) is a puriﬁed mixture of
AUX-I and AUX-II collagenases from C histolyticum that hydro-
lyses collagen under physiologic conditions and results in lysis of
collagen plaques.5 CCH has been approved by the US Food and
Drug Administration for the treatment of adult men with PDwho
have palpable collagenous plaques and penile curvature of at least
30 at the start of treatment. In a combined analysis of data from
two large randomized, double-blinded, placebo-controlled trials,
IMPRESS I and II, treatment with CCH resulted in a mean
decrease in penile curvature of 34% compared with 18.2% in
patients who received placebo (P < .0001).4 In addition, CCH
treatment was associated with signiﬁcant improvements compared
with placebo in the physical and psychological symptoms of PD.4
Based on these ﬁndings, the American Urological Association has
included CCH in its guidelines, to be used in combination with
penile plaque remodeling, for the decrease of penile curvature in
patients with stable PD, penile curvature of 30 to 90, and intact
erectile function.2
Another treatment strategy that has been shown to be
potentially efﬁcacious in decreasing penile curvature in patients
with PD is vacuum-pump therapy.6 Hence, the present pilot
study was performed to investigate the effect of vacuum-pump
therapy, with and without penile modeling, on the efﬁcacy and
safety of CCH administration for the management of PD.
METHODS
Study Design
The study was a prospective, randomized, open-label, pilot
study conducted at a single site in the United Kingdom from
October 2014 through March 2016 (ClinicalTrials.gov identiﬁer
NCT02267460). The study was conducted according to Good
Clinical Practice guidelines and the principles of the Declaration
of Helsinki, and the protocol was approved by the appropriate
independent ethics committee.
Patients
Men (age  18 years) with stable symptomatic PD, as deter-
mined by the investigator, were eligible for inclusion if they hadJ Sex Med 2017;14:1430e1437penile curvature of at least 30 in the dorsal, lateral, or dorsolateral
plane and if it was possible to delineate the plane of maximal
curvature. Principal exclusion criteria included penile curvature
less than 30 or greater than 90 at screening; other penile disorders
such as hourglass deformity, compromised penile hemodynamics,
or signiﬁcant erectile dysfunction that had failed to respond to oral
phosphodiesterase type 5 inhibitors; history of spontaneous pria-
pism; calciﬁed plaque that would preclude correct administration
of CCH; receipt of previous oral or intralesional medical therapies
for PD within 3 months of the ﬁrst dose of study drug or the use of
mechanical devices within 2 weeks of screening; and previous
surgery for PD. Written informed consent was obtained from all
patients before inclusion in the study.Treatments
Once patients met the entry criteria, an investigator requested
randomization of the patients into treatment groups through an
interactive web response system. Patients were stratiﬁed accord-
ing to the degree of baseline penile curvature (30e60 or >60)
and randomly assigned (1:1), through an interactive web
response system using a computer-generated randomization
allocation sequence with a block size of 4, to receive CCH plus
vacuum-pump therapy with investigator-administered plaque
modeling or CCH plus vacuum-pump therapy alone. Because of
the nature of the interventions, no blinding took place. Each
treatment cycle consisted of two intralesional injections of CCH
0.58 mg separated by approximately 24 to 72 hours. Injections
were given directly into the primary penile plaque. Up to four
approximately 6-week treatment cycles (ie, eight injections)
could be given, with intervals of 42 ± 5 days between cycles, if
penile curvature of at least 15 remained and the investigator
considered that further treatment was clinically indicated.
Vacuum-pump therapy was performed using the ErecAid
Esteem manual vacuum therapy system (Timm Medical Tech-
nologies, Inc, Fort Washington, PA, USA). Patients were
instructed to use the pump twice daily (morning and evening)
from 14 ± 2 days after the second injection of CCH in each
treatment cycle until the start of the next cycle. Vacuum-pump
therapy was continued until the ﬁrst follow-up visit (nominal
week 24). Before the ﬁrst use of the system, all patients received
training in the correct operation of the system and were required
to demonstrate that they could use the system safely and
correctly. For each application of vacuum therapy, a vacuum was
created for 5 to 10 seconds until an adequate erection was ob-
tained. Tension rings or other devices were not used to aid
erection. Once the penis was erect, the vacuum was maintained
for 30 seconds before release. These steps were performed ﬁve
times during each treatment session.
Plaque modeling by the investigator or other designated
personnel was performed 24 to 72 hours after the second
injection of CCH in each treatment cycle. Local anesthesia
before modeling was given if requested by the patient. During
modeling, the investigator grasped the hardened portion or
1432 Ralph et alplaque of the non-erect penis approximately 1 cm on either side
of the site of injection and applied steady pressure to elongate
and stretch the penis. This pressure was held for 30 seconds and
then released. This procedure was repeated twice at 30-second









Age (y), mean (SD) 57.8 (9.4) 57.6 (8.4)
Race, n (%)
White 15 (100) 14 (93.3)
Asian 0 1 (6.7)
Erectile dysfunction, n (%) 6 (40.0) 5 (33.3)
Trauma to penis reported, n (%) 4 (26.7) 3 (20.0)
Direction of penile curvature, n (%)Assessments
Penile curvature was measured before the administration of
CCH at the beginning of each treatment cycle and during
follow-up visits at nominal weeks 24 and 36. Curvature was
measured three times after prostaglandin E1 induction of an
erection using a goniometer protractor device. The Peyronie’s
Disease Questionnaire (PDQ)7 and the International Index of
Erectile Function (IIEF) questionnaire8 were completed at
nominal week 36 to assess the physical, psychological, and sexual
effects of CCH therapy. The primary efﬁcacy end point was the
percentage of change in penile curvature from baseline to
nominal week 36. Additional efﬁcacy end points included
change from baseline to nominal week 36 in PDQ bother score
(PDQ questions 10e15), PD symptom severity score (PDQ
questions 1e6), penile pain score (PDQ questions 7e9), and
IIEF domain scores (erectile function, questions 1e5 and 15;
orgasmic function, questions 9 and 10; sexual desire, questions
11 and 12; intercourse satisfaction, questions 6e8; and overall
satisfaction, questions 13 and 14; each IIEF question was rated
from 0 [“worst”] to 5 [“best”]).8 The rate of composite
responders, deﬁned as patients who had at least a 20% decrease
in penile curvature from baseline and a decrease in PDQ bother
score of at least 1 point from baseline or a change from reporting
“no sexual activity” to reporting “sexual activity,” also was
assessed at nominal week 36. Also at week 36, patients were
asked to rate the overall change in symptoms and effects of PD
on their lives, using the Global Assessment of Peyronie’s Disease
assessment tool, a seven-point scale that rates improvement from
baseline as “much improved” (3) to “much worse” (3). A
global assessment responder was deﬁned as a patient who
reported small but important improvement, moderate
improvement, or much improvement in the overall global
assessment question score. Safety was assessed throughout the
study by monitoring adverse events (AEs) and vital signs, clinical
laboratory investigations, and assessments of the IIEF erectile
function domain.Right lateral 1 (6.7) 0
Dorsal 9 (60.0) 10 (66.7)
Left dorsolateral 5 (33.3) 5 (33.3)
Penile plaques, n (%)
1 12 (80.0) 14 (93.3)
2 2 (13.3) 1 (6.7)
>2 1 (6.7) 0
Penile curvature (), mean (SD) 59.0 (15.0) 58.3 (12.2)
Severity of penile curvature, n (%)
60 10 (66.7) 10 (66.7)
>60 5 (33.3) 5 (33.3)
CCH ¼ collagenase Clostridium histolyticum.Statistical Methods
Sample size was not formally calculated; however, the study
sponsor stated that a sample of approximately 30 patients would
be adequate for this pilot study. The intent-to-treat (ITT) pop-
ulation consisted of all enrolled patients who had at least one
injection of CCH. Efﬁcacy analyses were performed in the
modiﬁed ITT population, which included all enrolled patients
who received at least one injection of CCH, had a penile cur-
vature measurement at screening, and at least one post-treatment
penile curvature measurement. Primary and other efﬁcacy endpoints were summarized using descriptive statistics unless
otherwise indicated. For the assessment of PDQ domain scores,
if answers to more than 50% of the items within the domain
were missing, then the domain score was said to be missing; if no
more than 50% of the items were missing, then the domain score
was calculated as the average of available item scores multiplied
by the total number of items in that domain. For the analysis of
change variables, missing data were imputed using the last
observation carried forward (LOCF) method. Between-group
differences in continuous end points (eg, change from baseline)
were assessed using analysis of variance with treatment group as a
factor. For categorical end points (eg, responder analyses), the
odds ratio for response between groups was calculated and the
corresponding 95% CI was estimated assuming an asymptotic
normal distribution. Calculations were performed using SAS 9.3
(SAS Institute, Cary, NC, USA).RESULTS
Thirty-six patients were screened; of these, 30 patients were
enrolled and randomly assigned to treatment. Overall, the two
groups of 15 patients were similar in baseline demographics and
disease characteristics (Table 1). Most patients had a penile
curvature no greater than 60. All 30 patients were included in
the ITT and modiﬁed ITT populations. Most patients in the
two treatment groups completed the study (Figure 1). One
patient in each treatment group received penile anesthesia before





CCH 0.58 mg +
vacuum
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(n = 13, 86.7%)
Completed
(n = 12, 80.0%)
Figure 1. Patient disposition. CCH ¼ collagenase Clostridium histolyticum.
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Mean penile curvature at baseline was similar for the two
treatment groups. At week 36, a similar improvement in penile
curvature was observed in the two groups (mean change from
baseline ¼ 23.7 [SD ¼ 10.9] for CCH þ
vacuum þ modeling and 23.3 [SD ¼ 7.2] for CCH þ vac-
uum; between-group difference ¼ 0.3, 95% CI ¼ 7.3 to
6.6). The mean percentage of decrease from baseline to week 36
also was similar in the two treatment groups (Figure 2).
In addition, improvements in the PDQ scores on the
symptom severity and bother domains from baseline to week 36
were observed in the two treatment groups (Table 2). Mean
change in PD symptom severity score (LOCF) was numerically
larger in the CCH plus vacuum group (mean change ¼ 6.4
[SD ¼ 2.8]) than in the CCH plus vacuum plus modeling
group (mean change ¼ 2.2 [SD ¼ 4.4]; treatment–39.3






















CCH + Vacuum + Modeling
(n = 15)
CCH + Vacuum 
(n = 15)
Figure 2. Mean change in penile curvature from baseline to week
36 (last observation carried forward analysis). Between-group
difference of 1.8% (95% CI ¼ 7.5 to 11.0). CCH ¼ collagenase
Clostridium histolyticum.
J Sex Med 2017;14:1430e1437difference ¼ 4.1, 95% CI ¼ 0.9 to 7.3). Mean change in PDQ
bother domain scores (SD; LOCF) also was numerically greater
in the CCH plus vacuum group (3.8 [SD ¼ 3.0]) compared
with the CCH plus vacuum plus modeling group (2.4
[SD ¼ 2.5]; treatment difference ¼ 1.4, 95% CI ¼ 0.9 to
3.8). Penile pain domain score increased from baseline (indi-
cating greater severity, pain, or bother) in the CCH plus vac-
uum plus modeling group (mean change from baseline ¼ 0.7
[SD ¼ 3.1], LOCF), but slightly decreased (suggesting
improvement) in the CCH plus vacuum group (mean change
from baseline ¼ 1.3 [SD ¼ 3.0], LOCF).
Mean IIEF erectile function and intercourse satisfaction scores
were improved from baseline for patients in the CCH plus
vacuum group, whereas slight worsening was observed in the
CCH plus vacuum plus modeling group (Table 3).8 The two
groups had an increase in mean IIEF overall satisfaction score
(indicating increased satisfaction) from baseline to week 36,
although greater improvement was observed in the CCH plus
vacuum group. In the group that received CCH plus vacuum
therapy with plaque modeling, the mean IIEF overall satisfaction
score was 5.9 (SD ¼ 2.5) at baseline and 6.1 (SD ¼ 2.8) at week
36—an increase of 0.3 point (SD ¼ 1.8). In comparison, the
baseline satisfaction score in the group that did not undergo
modeling was 4.7 (SD ¼ 2.3) compared with 6.8 (SD ¼ 2.5) at
week 36—a mean increase of 2.0 points (SD ¼ 2.6; between-
group difference ¼ 1.7 points, 95% CI ¼ 3.5 to 0.0).
The percentage of patients who reported a composite response
equaled 66.7% in the group that received CCH plus vacuum
plus modeling and 84.6% in the group that received CCH plus
vacuum without modeling. The odds ratio for composite
response in the group that underwent plaque modeling equaled
0.4 (95% CI ¼ 0.1 to 2.3).
Table 2. PDQ domain scores with CCH
PDQ domain score*
CCH þ vacuum




Baseline 1.4 (1.7) 4.0 (4.7)
Week 36 2.7 (3.2) 2.2 (2.4)
Change from baseline (LOCF) 0.7 (3.1) 1.3 (3.0) 2.0 (0.6 to 4.5)
Symptom severity
Baseline 9.3 (4.7) 12.5 (4.4)
Week 36 6.9 (3.9) 6.6 (5.4)
Change from baseline (LOCF) 2.2 (4.4) 6.4 (2.8) 4.1 (0.9e7.3)
Bother
Baseline 6.3 (2.8) 7.8 (3.2)
Week 36 4.4 (2.9) 4.0 (3.7)
Change from baseline (LOCF) 2.4 (2.5) 3.8 (3.0) 1.4 (0.9 to 3.8)
CCH ¼ collagenase Clostridium histolyticum; LOCF ¼ last observation carried forward; PDQ ¼ Peyronie’s Disease Questionnaire.
*Higher scores indicate greater severity, pain, or bother. Data are presented as mean (SD) unless otherwise indicated.
1434 Ralph et alMost patients in the CCH plus vacuum plus modeling
group and 92.3% of those in the CCH plus vacuum group
reported some degree of improvement (Figure 3). Of note,
53.3% and 69.2%, respectively, reported “moderate” and
“much” improvement. The odds ratio for global assessment
response (deﬁned as small but important, moderate, or much




þ modeling (n ¼ 15)
Erectile function (30)
Baseline 25.4 (3.2)
Week 36 22.7 (8.8)
Change from baseline (LOCF) 2.8 (10.4)
Orgasmic function (10)
Baseline 8.8 (1.9)
Week 36 7.8 (3.7)
Change from baseline (LOCF) 1.0 (4.1)
Sexual desire (10)
Baseline 6.6 (2.0)
Week 36 6.3 (2.3)
Change from baseline (LOCF) 0.3 (1.6)
Intercourse satisfaction (15)
Baseline 9.5 (3.3)
Week 36 8.7 (4.3)
Change from baseline (LOCF) 0.8 (4.5)
Overall satisfaction (10)
Baseline 5.9 (2.5)
Week 36 6.1 (2.8)
Change from baseline (LOCF) 0.3 (1.8)
Data are presented as mean (SD) unless otherwise indicated.
CCH ¼ collagenase Clostridium histolyticum; IIEF ¼ International Index of Erect
*Higher scores indicate greater frequency; less difﬁculty; or higher satisfactionSafety and Tolerability
In the two groups, all patients reported at least one AE, andmost
AEs were mild or moderate in intensity. Only one patient, in the
group undergoing plaque modeling, reported a severe AE (epi-
lepsy). The most commonly reported AEs in the two groups were
penile contusion, swelling, or pain (Table 4). No cases of corporal





1.9 (5.5) 4.7 (11.4 to 2.1)
8.8 (2.0)
8.5 (2.4)
0.3 (2.6) 0.7 (3.5 to 2.2)
7.1 (1.6)
7.2 (1.2)
0.1 (1.4) 0.2 (1.4 to 1.0)
8.1 (4.0)
8.5 (4.8)
0.8 (5.4) 1.5 (5.5 to 2.5)
4.7 (2.3)
6.8 (2.5)
2.0 (2.6) 1.7 (3.5 to 0.0)
ile Function; LOCF ¼ last observation carried forward.
, conﬁdence, or pleasure.8
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CCH + Vacuum + Modeling (n = 15)
CCH + Vacuum (n = 15)
Figure 3. Global Assessment of Peyronie’s Disease responses at week 36 (last observation carried forward analysis). CCH ¼ collagenase
Clostridium histolyticum.
CCH and Vacuum Therapy in Peyronie’s Disease 1435(myocardial ischemia and pericarditis, n¼ 1 each) were reported in
the CCH plus vacuum plus modeling group. The serious AE of
pericarditis was considered by investigators to be mild in intensity
and occurred after treatment (day 232). Another serious AE,
myocardial ischemia of mild intensity, occurred during the second
CCH injection of the patient’s second treatment cycle (day 55).
Neither serious AE required dose adjustment or was considered by
the investigator to be related to treatment.DISCUSSION
Multiple conservative therapies (eg, penile modeling, traction
therapy, and vacuum therapy) have been investigated as treat-
ment options for PD based on their ability to facilitate ﬁbrous
plaque remodeling and lengthen and/or straighten the penis.1,9Table 4. Most commonly reported AEs*
AE, n (%)
CCH þ vacuum
þ modeling (n ¼ 15)
CCH þ vacuum
(n ¼ 15)
Any AE 15 (100.0) 15 (100.0)
Penile contusion 13 (86.7) 15 (100.0)
Penile swelling 11 (73.3) 15 (100.0)
Penile pain 8 (53.3) 5 (33.3)
Contusion 3 (20.0) 2 (13.3)
Arthralgia 2 (13.3) 0
Inﬂuenza 1 (6.7) 2 (13.3)
Injection-site swelling 1 (6.7) 2 (13.3)
Penile erythema 0 2 (13.3)
URTI 0 3 (20.0)
AE ¼ adverse event; CCH ¼ collagenase Clostridium histolyticum; URTI ¼
upper respiratory tract infection.
*At least 10% of patients in either group.
J Sex Med 2017;14:1430e1437Intralesional injection of CCH is approved for the treatment of
PD in adult men with palpable plaque and curvature deformity
of at least 30 at therapy initiation. CCH is typically applied in
conjunction with penile modeling based on the design of phase 3
trials (in which investigators and patients performed penile
modeling for 6 weeks after each CCH treatment cycle).4 Because
penile modeling and vacuum therapy share underlying physio-
logic mechanisms, the objective of this pilot study was to evaluate
a new CCH treatment regimen that included vacuum-pump
therapy (with or without modeling) in the management of sta-
ble PD in adult men with penile curvature of at least 30.
Treatment with CCH plus vacuum alone or in combination with
modeling improved penile curvature by approximately 40%
(equivalent to a decrease of approximately 23). This is slightly
greater than the change in penile curvature from baseline (mean
improvement from baseline ¼ 17.2) reported by an open-label
study that used vacuum therapy combined with modeling as part
of a modiﬁed CCH treatment protocol (three CCH injections
[0.9 mg] separated by 4 weeks).10 Furthermore, these results add
credence to the ﬁndings of a small, uncontrolled, 12-week study
that demonstrated improvement in penile curvature with
vacuum-pump (Osbon ErecAid, MediPlus, High Wycombe,
UK) therapy alone.6
In general, PDQ domain scores, including the bother domain,
improved with CCH plus vacuum with or without modeling,
which reﬂected the relief of PD symptoms and the potential
enhancement of quality of life. In the two treatment groups, the
decreases in mean PDQ bother scores were generally comparable
with those reported forCCH-treated patients in IMPRESS I and II
(mean decrease ¼ 2.8 points).4 The decrease in bother scores was
numerically greater in the CCH plus vacuum group, which might
reﬂect less manipulation of the penis and, hence, less patient
1436 Ralph et aldiscomfort. However, in the absence of a formal statistical analysis,
it is not possible to draw any ﬁrm conclusions about the signiﬁ-
cance of these ﬁndings. There was little change in the IIEF overall
satisfaction score in the group that underwent plaque modeling
(mean¼ 0.3), whereas the two-point change observed in the group
that did undergo plaque modeling was numerically larger than the
change reported in the IMPRESS I and II trials4 and could reﬂect
patient preference for limited penile manipulation in the CCH
plus vacuum group. Furthermore, worsening of erectile function
domain scores in the CCH plus vacuum plus modeling group
(mean change from baseline¼2.8) could be an artifact of penile
discomfort attributable to penile modeling. Other changes from
baseline in the CCH plus vacuum plus modeling group in IIEF
domain scores were small (mean change from baseline ¼ 0.8
to 1.0) and likely attributable to the subjective nature of the
questionnaire.
The composite response rate (66.7% and 84.6% for the CCH
plus vacuum plus modeling and CCH plus vacuum groups,
respectively) and the global assessment response rate (86.7% and
92.3%, respectively) at 36 weeks were numerically higher than the
corresponding rates seen with CCH plus modeling at 52 weeks in
combined analyses of the IMPRESS I and II trials (60.8% and
46.6% for global assessment responder and composite responder,
respectively), which used identical deﬁnitions of global assessment
and composite response.4 In addition, in this study, responder rates
were higher in the two treatment groups compared with those of
patients who received placebo (ie, sham injection and investigator
modeling) in the IMPRESS trials (29.5% for global assessment
responders and 28.0% for composite responders),4 suggesting that
CCH plus vacuum-pump therapy (alone or in combination with
modeling) provided adequate remodeling of the ﬁbrosis plaque.
However, the clinical signiﬁcance of these ﬁndings remains to be
established in a larger patient population, particularly because
composite response and global assessment responder end points
included subjective reports of patient improvement, which could
have been inﬂuenced by factors other than treatment (eg, increased
psychologic distress caused by treatment or expectation of
improvement [placebo effect]).
The most common AEs in the present study were consistent
with those experienced by patients in the IMPRESS trials, in
which the most common AEs, which occurred in 45% to 80% of
patients who received CCH plus modeling, were penile ecchy-
mosis, penile swelling, and penile pain.4 The concordance in AE
proﬁles between the present study and the IMPRESS trials
suggests that concomitant vacuum-pump therapy does not sub-
stantially negatively affect the tolerability of CCH treatment. It is
important to note that vacuum therapy was initiated 2 weeks
after the last CCH injection to minimize the risk of some AEs,
such as ecchymosis and hematoma; earlier initiation of vacuum
therapy could increase the risk of some AEs.
The present study has the limitations inherent in pilot trial
designs, including a small sample, lack of formal statistical
analyses, and limited follow-up duration. In addition, furtherresearch is needed to optimize the duration and frequency of
vacuum-pump administration and identify characteristics of
patients for whom vacuum-pump therapy would be most
beneﬁcial. Nevertheless, the results warrant additional studies in
larger patient populations to determine whether the combination
of CCH and vacuum-pump therapy could be a useful addition to
the therapeutic options for the management of PD.
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